This Article Full Text Full Text (PDF) All Versions of this Article: 118/24/2533    most recent CIRCULATIONAHA.108.792986v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frankel, D. S. Articles by Tofler, G. H. Search for Related Content PubMed PubMed Citation Articles by Frankel, D. S. Articles by Tofler, G. H. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information Diabetes Genetics Home Reference Related Collections Risk Factors Arterial thrombosis Aggregation Type 2 diabetes Epidemiology Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors Related Article

(Circulation. 2008;118:2533-2539.)
© 2008 American Heart Association, Inc.

Epidemiology

Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease

The Framingham Offspring Study

David S. Frankel, MD; James B. Meigs, MD, MPH; Joseph M. Massaro, PhD; Peter W.F. Wilson, MD; Christopher J. O'Donnell, MD, MPH; Ralph B. D'Agostino, PhD; Geoffrey H. Tofler, MD

From the Division of Cardiovascular Medicine (D.S.F.), Department of Medicine, University of Pennsylvania, Philadelphia, Pa; the General Medicine Division (J.B.M.) and the Cardiology Division (C.J.O.), Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston; the National Heart, Lung, and Blood Institute’s Framingham Heart Study (J.M.M., C.J.O., R.B.D), Framingham, Mass; the Division of Cardiology (P.W.F.W.), Department of Medicine, Emory University School of Medicine, Atlanta, Ga; the Department of Biostatistics (J.M.M., R.B.D.), Boston University, Boston, Mass; and the Royal North Shore Hospital (G.H.T.), Sydney, Australia.

Correspondence to James B. Meigs, MD, MPH, General Medicine Division, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114. E-mail jmeigs{at}partners.org

Received May 18, 2008; accepted September 30, 2008.

Background— Von Willebrand factor (vWF) is inconsistently associated with cardiovascular disease (CVD). This might be explained by associations of vWF with type 2 diabetes mellitus and insulin resistance.

Methods and Results— We tested whether vWF predicted incident CVD in 3799 Framingham Offspring Study participants, and in particular, among those with type 2 diabetes mellitus or insulin resistance. During 11 years of follow-up, 351 participants developed CVD. In proportional hazards models (with adjustment for age, sex, blood pressure, smoking, body mass index, total and high-density lipoprotein cholesterol, and treatment with aspirin, insulin, antihypertensives, and lipid-lowering medications) with the lowest quartile of the vWF distribution as the referent, the hazard ratio (HR) for CVD was 0.94 in the second quartile, 0.98 in the third, and 1.32 in the highest (P=0.04 for trend). Additional adjustment for type 2 diabetes mellitus or insulin resistance (homeostasis model) partially attenuated the association (multivariable HRs for top quartile 1.28 and 1.21, respectively). We then stratified the models by diabetes status or the homeostasis model of insulin resistance distribution (top quartile versus lower 3 quartiles). vWF was associated with CVD among participants with diabetes mellitus (HR for top quartile relative to bottom 1.47, P=0.04 for trend) but not among nondiabetic participants (HR 1.15, P=0.5) and similarly among insulin-resistant (HR 1.50, P=0.01) but not insulin-sensitive (HR 1.02, P=0.9) participants.

Conclusions— Higher levels of vWF were associated with risk of CVD in people with type 2 diabetes mellitus or insulin resistance, which suggests that vWF may be a risk factor unique to these populations.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 2485-2487. [Extract] [Full Text]

This article has been cited by other articles:

				D. Voora, S. H. Shah, I. Spasojevic, S. Ali, C. R. Reed, B. A. Salisbury, and G. S. Ginsburg The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1609 - 1616. [Abstract] [Full Text] [PDF]